Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Cachexia, Sarcopenia and Muscle
Metadata
Title
Erratum to: Assessing sarcopenic prevalence and risk factors in residential aged care: methodology and feasibility
Authors
Timothy R. Henwood
Justin W. Keogh
Natasha Reid
Will Jordan
Hugh E. Senior
Publication date
01-09-2014
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cachexia, Sarcopenia and Muscle / Issue 3/2014
Print ISSN: 2190-5991
Electronic ISSN: 2190-6009
DOI
https://doi.org/10.1007/s13539-014-0151-0

Other articles of this Issue 3/2014

Journal of Cachexia, Sarcopenia and Muscle 3/2014 Go to the issue

Editorial

An invitation to the 2nd Cancer Cachexia Conference, Montréal, Canada

Original Article

1-Sarcosine–angiotensin II infusion effects on food intake, weight loss, energy expenditure, and skeletal muscle UCP3 gene expression in a rat model

Original Article

Anabolic exercise in haemodialysis patients: a randomised controlled pilot study

Original Article

Identifying recreational physical activities associated with muscle quality in men and women aged 50 years and over

Editorial

Resistance exercise: an effective strategy to reverse muscle wasting in hemodialysis patients?

Letter to the Editor

Left ventricular mass correlates with lean body mass in patients with disease-associated wasting
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits